Most uveitis-related vision loss is the result of chronic inflammation of the posterior segment of the eye (i.e., intermediate, posterior, and panuveitis). Although noninfectious anterior uveitis is typically treated successfully with topical corticosteroids, noninfectious uveitis of the posterior segment (NIU-PS) can be more difficult to manage. Corticosteroids (e.g., topical, systemic) remain the clinical mainstay for this type of uveitis, but the use of other immunomodulators, such as tumor necrosis factor (TNF)-alpha inhibitors, has become increasingly widespread. Given the competitive NIU-PS therapy market, it is essential to understand the use of current therapies in the nuanced treatment algorithm using real-world data.
- What patient share do key therapies and brands garner by line of therapy in newly diagnosed NIU-PS patients? What are the quarterly trends in prescribing among recently treated and newly diagnosed NIU-PS patients?
- How has AbbVie’s Humira, which was approved for noninfectious intermediate, posterior, and panuveitis in 2016, been integrated into the treatment algorithm, and what is its source of business?
- What proportion of NIU-PS patients receive drug therapy within one year of diagnosis, and how quickly? What percentage of patients progress to later lines of therapy within one year of diagnosis?
- What percentage of NIU-PS patients are treated with monotherapy versus combination therapy? What are the most commonly used combinations?
- What are the product-level compliance and persistency rates among drug-treated patients with NIU-PS?
Geographies: United States
Real-world data: Longitudinal patient-level claims data analysis
Key drugs covered: Humira, Remicade, other TNF-alpha inhibitors, Ozurdex, Iluvien, Retisert, Lotemax, Durezol, Triesence, prednisolone, prednisone
Key analysis provided:
Brand/therapy usage across longitudinal patient sample
Newly diagnosed patient analysis
Treatment initiation and progression
Line of therapy analysis
Combination therapy analysis
Source of business for recently treated patients
Persistency and compliance analysis
Product-level patient flowcharts
Treatment Algorithms: Claims Data Analysis provides detailed, quantitative analysis of the treatment journey and brand usage across lines of therapy and overall using real-world, patient-level claims data so that marketers can accurately assess their source of business, benchmark usage against competitors, and quantify areas of opportunity for their marketed or emerging brand.
- Uveitis - Current Treatment - Detailed, Expanded Analysis - Treatment Algorithms - Claims Data Analysis (US)
- Treatment Algorithms CDA Noninfectious Uveitis of the Posterior Segment US February 2019
Author(s): Himanshu Jain, M.S. Pharm
Himanshu joined the CNS / ophthalmology team at Decision Resources Group in 2016. He has authored content for psychiatry and ophthalmology (retinal / nonretinal) indications, including schizophrenia, age-related macular degeneration, diabetic retinopathy / diabetic macular edema, dry eye disease, glaucoma, and uveitis.
Himanshu has more than ten years of experience working in market research and consulting firms, and has managed multiple market assessment projects, including bottom-up forecasts, across multiple therapy areas. He holds a M.S. degree in Pharmacology and Toxicology from the National Institute of Pharmaceutical Education and Research in India and an Executive Post-Graduate Diploma in International Business from the Indian Institute of Foreign Trade.